The estrogen receptor (ER) content of breast carcinoma is generally accepted as valuable in
predicting clinical outcome and tumour response to hormonal manipulation. We applied a …

Estrogen receptor (ER) status of breast carcinomas determines prognosis and treatment.
Biochemical ER assays are expensive and time-consuming and require fresh tumor …

Cytological imprint material from 26 mammary carcinomas was stained with monoclonal
antibodies to oestrogen and progesterone receptors in an immunoperoxidase procedure …

The authors immunohistochemically assessed the presence of estrogen receptor (ER) in
formalin-fixed, paraffin-embedded tissue sections of 68 breast carcinomas by an automated …

Monoclonal antibody to human estrogen receptor (ER) provides a useful
immunohistochemical tool for the evaluation of ER content in breast carcinoma, but visual …

Four methods of assessing oestrogen receptor (ER) status were compared in 33 patients
with operable primary breast cancer. the methods used to assess the ER status were …

Variation in tissue fixation, processing, and staining is largely responsible for poor
reproducibility of estrogen receptor (ER) immunohistochemistry assays. A frozen, agar …

BACKGROUND The techniques for immunostaining estrogen receptor (ER) in cytologic
specimens have varied, as have the detection rates. The authors compared various fixation …

Immunohistochemical analysis is used routinely to determine the estrogen receptor (ER)
status of breast cancers in paraffin sections. However, lack of standardization has raised …

The immunohistochemical estrogen receptor (ER) assay quantitated by image analysis was
compared with the biochemical dextran-coated charcoal (DCC) assay in 97 primary breast …